Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Filovirus Post-Exposure Prophylaxis, preparedness and efficacy evaluation during outbreak in Central and West-Africa

Obiettivo

In May 2026, a Bundibugyo virus disease (BVD) outbreak was reported in Democratic Republic of Congo (DRC), highlighting the urgent need for effective medical countermeasures, as no licensed vaccine or therapeutic is currently available against this Ebola species. The EBO-PEP project was funded by EDCTP in 2024 to evaluate a post-exposure prophylaxis (PEP) strategy against Ebola virus disease (EVD). Beyond its initial objective, EBO-PEP enabled the consortium to establish a robust outbreak research platform, designed as a preparedness tool rapidly activatable across filovirus species. The emergence of the current BVD outbreak in Eastern DRC provides the first opportunity to implement this framework. The consortium has adapted the EVD protocol to the BVD context, mobilizing the infrastructure, partnerships, and operational capacities already in place. Among the candidate interventions, obeldesivir (ODV), an orally administered broad-spectrum antiviral prioritized by the WHO R&D Blueprint, is evaluated as PEP in a randomized trial. Remdesivir (RDV), with an established safety profile in children and pregnant women, is proposed for vulnerable populations excluded from the randomized trial. The EBO-PEP consortium brings together African and European institutions with complementary expertise in filovirus research and clinical trial implementation in outbreak settings. The overall objective of this project is to increase the portfolio of therapeutic tools against BDBV by evaluating a PEP strategy for high-risk contacts in Eastern DRC. To address this objective, we focus our activities on two specific objectives: (i) to set up a randomized, placebo-controlled phase III clinical trial in Eastern DRC to test the efficacy of ODV used as PEP for high-risk contacts; and (ii) to set up a parallel prospective interventional cohort to generate evidence on the safety, feasibility, and effectiveness of RDV as PEP in children under 12 years and pregnant or breastfeeding women.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-JU-GH-EDCTP3-2026-01-EBOLA-IBA

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contributo netto dell'UE
€ 2 025 765,70
Indirizzo
RUE DE TOLBIAC 101
75654 Paris
Francia
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 2 165 809,45

Partecipanti (7)